Egetis Therapeutics AB (LTS:0ABW) Cyclically Adjusted Revenue per Share: kr0.54 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0ABW Egetis Therapeutics AB LTS:0ABW
61 GF Score
Price kr6.27
GF Value kr5.64
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Egetis Therapeutics AB Cyclically Adjusted Revenue per Share?

Egetis Therapeutics AB LTS:0ABW -5.57% 61 Cyclically Adjusted Revenue per Share is kr0.54 as of Mar. 2026. GuruFocus rates LTS:0ABW with a GF Score™ of 61/100 and a GF Value™ of kr5.64 (Modestly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Egetis Therapeutics AB's adjusted revenue per share for the three months ended in Mar. 2026 was kr0.033. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is kr0.54 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Egetis Therapeutics AB's average Cyclically Adjusted Revenue Growth Rate was -6.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -8.20% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -6.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-23), Egetis Therapeutics AB's current stock price is kr6.27. Egetis Therapeutics AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was kr0.54. Egetis Therapeutics AB's Cyclically Adjusted PS Ratio of today is 11.61.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Egetis Therapeutics AB was 27.37. The lowest was 4.30. And the median was 8.03.


Egetis Therapeutics AB  (LTS:0ABW) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Egetis Therapeutics AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=6.27/0.54
=11.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Egetis Therapeutics AB was 27.37. The lowest was 4.30. And the median was 8.03.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Egetis Therapeutics AB Cyclically Adjusted Revenue per Share Related Terms


Egetis Therapeutics AB Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Egetis Therapeutics AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Egetis Therapeutics AB Cyclically Adjusted Revenue per Share Chart

Egetis Therapeutics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.65 0.60 0.55

Egetis Therapeutics AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.56 0.55 0.57 0.55 0.54

LTS:0ABW vs VRTX, REGN, ALNY: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Egetis Therapeutics AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Egetis Therapeutics AB Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Egetis Therapeutics AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Egetis Therapeutics AB's Cyclically Adjusted PS Ratio falls into.


LTS:0ABW
61GF Score
Egetis Therapeutics AB LTS:0ABW
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Egetis Therapeutics AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Egetis Therapeutics AB's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.033/133.5600*133.5600
=0.033

Current CPI (Mar. 2026) = 133.5600.

Egetis Therapeutics AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.000 101.019 0.000
201609 0.000 101.138 0.000
201612 0.000 102.022 0.000
201703 0.000 102.022 0.000
201706 0.003 102.752 0.004
201709 0.000 103.279 0.000
201712 0.252 103.793 0.324
201803 0.014 103.962 0.018
201806 0.180 104.875 0.229
201809 0.125 105.679 0.158
201812 0.206 105.912 0.260
201903 1.020 105.886 1.287
201906 0.079 106.742 0.099
201909 0.104 107.214 0.130
201912 0.359 107.766 0.445
202003 0.201 106.563 0.252
202006 0.368 107.498 0.457
202009 0.044 107.635 0.055
202012 0.027 108.296 0.033
202103 0.021 108.360 0.026
202106 0.139 108.928 0.170
202109 0.034 110.338 0.041
202112 0.018 112.486 0.021
202203 0.039 114.825 0.045
202206 0.024 118.384 0.027
202209 0.024 122.296 0.026
202212 0.034 126.365 0.036
202303 0.028 127.042 0.029
202306 0.023 129.407 0.024
202309 0.049 130.224 0.050
202312 0.112 131.912 0.113
202403 0.041 132.205 0.041
202406 0.046 132.716 0.046
202409 0.032 132.304 0.032
202412 0.031 132.987 0.031
202503 0.035 132.825 0.035
202506 0.040 133.699 0.040
202509 0.048 133.480 0.048
202512 0.045 133.390 0.045
202603 0.033 133.560 0.033

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of kr0.54 mean?
Egetis Therapeutics AB (LTS:0ABW) has a Cyclically Adjusted Revenue per Share of kr0.54 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Egetis Therapeutics AB and its competitors.
Is Egetis Therapeutics AB's Cyclically Adjusted Revenue per Share too high?
Egetis Therapeutics AB's current Cyclically Adjusted Revenue per Share is kr0.54. Overall, Egetis Therapeutics AB has a GF Score™ of 61/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Egetis Therapeutics AB's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Egetis Therapeutics AB's Cyclically Adjusted Revenue per Share of kr0.54 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Egetis Therapeutics AB and its competitors. Egetis Therapeutics AB's current Cyclically Adjusted Revenue per Share is kr0.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egetis Therapeutics AB stock overvalued right now?
Based on GuruFocus' analysis, Egetis Therapeutics AB (LTS:0ABW) is currently considered Modestly Overvalued. The stock's GF Value™ is kr5.64, compared to a current price of kr6.27 — trading 11.2% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is kr0.54. Egetis Therapeutics AB's overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Egetis Therapeutics AB (LTS:0ABW), the current Cyclically Adjusted Revenue per Share is kr0.54 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Egetis Therapeutics AB (LTS:0ABW) Overvalued in 2026?

Based on GuruFocus' analysis, Egetis Therapeutics AB stock appears to be overvalued. The current stock price of kr6.27 is trading 11.2% above its estimated GF Value™ of kr5.64. GuruFocus considers Egetis Therapeutics AB to be Modestly Overvalued.

Key valuation signals for LTS:0ABW:

  • Cyclically Adjusted Revenue per Share: kr0.54
  • GF Value™: kr5.64 vs. price of kr6.27 (11.2% above fair value)
  • GF Score™: 61/100 with 7 warning signs

No single metric tells the full story. See the LTS:0ABW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Egetis Therapeutics AB Business Description

Address Grev Turegatan 11 C, Stockholm, SWE, 114 46
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
61GF Score

Get the complete analysis for LTS:0ABW

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr6.27
Price
kr5.64
GF Value